On May 2, 2022 XNK Therapeutics AB ("XNK") reported that an abstract on the long-term follow-up of the Phase I/II clinical trial study ACP-001 with its leading candidate drug has been selected for a presentation at European Hematology Association (EHA) (Free EHA Whitepaper)’s hybrid conference EHA (Free EHA Whitepaper)2022, which is held in Vienna, Austria, on June 9th-12th (Press release, XNK Therapeutics, MAY 2, 2022, View Source [SID1234613341]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract, titled Autologous NK Cells as Consolidation After Front-Line Stem Cell Transplantation in Multiple Myeloma: A Long-Term Follow-Up, will be presented by the first author Johan Lund at a poster session on Friday, June 10, 16:30 – 17:45 CEST. The other authors include Hareth Nahi, Stephan Meinke, Per-Henrik Holmqvist, Hans-Gustaf Ljunggren, Johan Aschan and Evren Alici.

"We are very happy to be able to present this clinical long-term follow-up at this prestigious conference. It further strengthens our belief in this exciting clinical program, which also includes an ongoing clinical Phase II combination study with Sanofi’s anti-CD38 antibody Sarclisa (Isatuximab)", said XNK’s CMO Johan Aschan.